Published in BMJ on June 26, 1999
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (2000) 10.66
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79
The effectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: a systematic review. PLoS Med (2013) 9.74
Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ (2013) 2.52
A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ (2007) 2.35
Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clin Pharmacol (2001) 2.25
Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. J Am Coll Cardiol (2015) 2.21
Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest (2013) 2.06
Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation (2008) 2.06
Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults. J Am Geriatr Soc (2012) 1.58
Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues. Qual Saf Health Care (2002) 1.57
Antiarrhythmic effects of beta3-adrenergic receptor stimulation in a canine model of ventricular tachycardia. Heart Rhythm (2007) 1.42
The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation. Diabetes Technol Ther (2015) 1.40
When not to use beta-blockers in seniors with hypertension. J Fam Pract (2008) 1.37
Beta blockers in hypertension and cardiovascular disease. BMJ (2007) 1.37
Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res (2012) 1.31
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag (2010) 1.16
Long-term medication adherence after myocardial infarction: experience of a community. Am J Med (2009) 1.14
Using an electronic medical record to identify opportunities to improve compliance with cholesterol guidelines. J Gen Intern Med (2001) 1.14
Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis (2005) 1.13
Prescription prevalence and continuing medication use for secondary prevention after myocardial infarction: the reality of care revealed by claims data analysis. Dtsch Arztebl Int (2011) 1.13
Implementing guidelines in primary care: can population impact measures help? BMC Public Health (2003) 1.10
The evolving epidemiology of acute coronary syndromes. Nat Rev Cardiol (2010) 1.09
Revisiting medication use in a frail 93-year-old man experiencing possible adverse effects. CMAJ (2013) 1.09
Collaborative cardiac care service: a multidisciplinary approach to caring for patients with coronary artery disease. Perm J (2008) 1.09
Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol (2000) 1.07
Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction. CMAJ (2008) 1.07
Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc (2010) 1.06
Improved survival of diabetic foot ulcer patients 1995-2008: possible impact of aggressive cardiovascular risk management. Diabetes Care (2008) 1.05
Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis (2007) 1.04
Weather-induced ischemia and arrhythmia in patients undergoing cardiac rehabilitation: another difference between men and women. Int J Biometeorol (2008) 1.01
Reducing all-cause mortality among patients with psychiatric disorders: a population-based study. CMAJ (2012) 1.00
Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart (2001) 0.99
Fifth report on the provision of services for patients with heart disease. Heart (2002) 0.99
RESPONSE study: Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists: Study design, objectives and expected results. Neth Heart J (2009) 0.99
Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. Am J Manag Care (2007) 0.96
Beta-blocker use and the changing epidemiology of out-of-hospital cardiac arrest rhythms. Resuscitation (2007) 0.95
A meta-analysis review of the effects of recombinant bovine somatotropin. 1. Methodology and effects on production. Can J Vet Res (2003) 0.94
Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. Br J Sports Med (2015) 0.93
Identifying opportunities for a medical group to improve outcomes for patients with coronary artery disease and heart failure: an exploratory study. Perm J (2011) 0.93
Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res (2014) 0.93
Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev (2004) 0.93
Early intravenous beta-blockers in patients with acute coronary syndrome--a meta-analysis of randomized trials. Int J Cardiol (2012) 0.92
Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol (2007) 0.92
Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner. J Am Coll Cardiol (2012) 0.92
Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies. Qual Saf Health Care (2006) 0.91
Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol (2007) 0.89
Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One (2012) 0.89
Cardiac medication prescribing and adherence after acute myocardial infarction in Chinese and South Asian Canadian patients. BMC Cardiovasc Disord (2011) 0.88
Acute myocardial infarction leads to acceleration of atherosclerosis. Atherosclerosis (2013) 0.88
Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol (2008) 0.88
Do immigrants from Turkey, Pakistan and Yugoslavia receive adequate medical treatment with beta-blockers and statins after acute myocardial infarction compared with Danish-born residents? A register-based follow-up study. Eur J Clin Pharmacol (2010) 0.88
β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ (2016) 0.87
Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006. BMC Public Health (2012) 0.87
Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease. J Epidemiol Community Health (2005) 0.87
Assessment and management of resistant hypertension. CMAJ (2014) 0.86
Development and evaluation of an improved methodology for assessing adherence to evidence-based drug therapy guidelines using claims data. AMIA Annu Symp Proc (2007) 0.86
Recent advances in the diagnosis and treatment of acute myocardial infarction. World J Cardiol (2015) 0.85
Is β-blocker (atenolol) a preferred antihypertensive in acute intracerebral hemorrhage? Neurol Sci (2012) 0.84
After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol (2006) 0.84
Challenges in assessing the process-outcome link in practice. J Gen Intern Med (2015) 0.84
Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res (2014) 0.84
Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention? Postgrad Med J (2005) 0.84
Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vasc Health Risk Manag (2007) 0.84
The predicted impact of heart disease prevention and treatment initiatives on mortality in Lithuania, a middle-income country. Prev Chronic Dis (2011) 0.83
β-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol (2014) 0.83
Processes of care and outcomes for community-acquired pneumonia. Am J Med (2011) 0.83
Major beta blocker mortality trials in chronic heart failure: a critical review. Heart (1999) 0.83
Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension. Vasc Health Risk Manag (2009) 0.83
Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it "ok" to discontinue? Curr Cardiol Rev (2012) 0.83
Income-related inequity in initiation of evidence-based therapies among patients with acute myocardial infarction. J Gen Intern Med (2011) 0.83
Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging (2012) 0.82
Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials. ISRN Cardiol (2013) 0.82
Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol (2015) 0.82
Exposure to ACEI/ARB and β-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer. Transl Oncol (2013) 0.81
Management and outcomes of renal disease and acute myocardial infarction. Am J Med (2010) 0.81
Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium. Br J Pharmacol (2001) 0.81
ACE up the sleeve - are vascular patients medically optimized? Vasc Health Risk Manag (2011) 0.81
Outcomes of after-hours versus regular working hours primary percutaneous coronary intervention for acute myocardial infarction. BMJ Qual Saf (2011) 0.81
Beta-blockers and the treatment of hypertension: it is time to move on. Cardiovasc J Afr (2007) 0.81
[The impact of the Multicenter Automatic Defibrillator Implantation Trial II in a university hospital--do all patients with myocardial infarction and reduced left ventricular function need an implantable cardioverter-defibrillator?]. Wien Klin Wochenschr (2003) 0.81
Effect of β-blockers on cardiac and pulmonary events and death in older adults with cardiovascular disease and chronic obstructive pulmonary disease. Med Care (2014) 0.80
Effect of drug combinations on admission for recurrent myocardial infarction. Heart (2007) 0.80
Debate: A subversive view of subsets - a dissident clinician's opinion. Curr Control Trials Cardiovasc Med (2000) 0.80
Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery. Cardiovasc Diagn Ther (2015) 0.80
Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus. BMC Cardiovasc Disord (2014) 0.79
Class effect of beta-blockers in survivors of ST-elevation myocardial infarction: A nationwide cohort study using an insurance claims database. Sci Rep (2015) 0.79
GNAS gene variants affect β-blocker-related survival after coronary artery bypass grafting. Anesthesiology (2014) 0.79
Dialysis: Phosphorus binders and survival: need for randomized trials. Nat Rev Nephrol (2009) 0.79
Myocardial infarction (ST-elevation). BMJ Clin Evid (2011) 0.79
Emerging clinical role of ranolazine in the management of angina. Ther Clin Risk Manag (2010) 0.79
Anti-ischemic therapy and stress testing: pathophysiologic, diagnostic and prognostic implications. Cardiovasc Ultrasound (2004) 0.79
Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study). Am J Cardiol (2010) 0.79
Smoking status and survival: impact on mortality of continuing to smoke one year after the angiographic diagnosis of coronary artery disease, a prospective cohort study. BMC Cardiovasc Disord (2014) 0.78
Anticoagulation after anterior myocardial infarction and the risk of stroke. PLoS One (2010) 0.78
Coronary artery disease. Are β-blockers truly helpful in patients with CAD? Nat Rev Cardiol (2012) 0.78
Pre-hospital ECG for acute coronary syndrome in urban India: a cost-effectiveness analysis. BMC Cardiovasc Disord (2010) 0.78
Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction. Heart Fail Rev (2004) 0.77
Changes in rates of beta-blocker use in community hospital patients with acute myocardial infarction. J Gen Intern Med (2004) 0.77
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA (1995) 45.41
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med (1998) 6.14
Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet (1974) 4.40
Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol (1991) 4.17
Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med (1995) 3.71
Use of secondary prophylaxis against myocardial infarction in the north of England. BMJ (1991) 3.63
Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Ann Intern Med (1995) 3.14
The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol (1977) 3.13
The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med (1990) 2.85
A likelihood approach to meta-analysis with random effects. Stat Med (1996) 2.54
Intravenous beta blockade in acute myocardial infarction. Should be used in combination with thrombolysis. BMJ (1998) 2.32
Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics (1986) 2.23
Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol (1997) 1.98
The evidence for beta blockers in heart failure. BMJ (1999) 1.84
The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med (1988) 1.83
Meta-analysis for 2 x 2 tables: a Bayesian approach. Stat Med (1992) 1.71
Increasing prescription of drugs for secondary prevention after myocardial infarction. BMJ (1995) 1.57
The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group. Eur Heart J (1988) 1.50
Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J (1997) 1.45
Beta blockers prevent cardiac death following a myocardial infarction: so why are so many infarct survivors discharged without beta blockers? Am J Cardiol (1996) 0.97
Deriving treatment recommendations from evidence within randomized trials. The role and limitation of meta-analysis. Int J Technol Assess Health Care (1999) 0.97
New Drugs. Beta-blockers and sympathomimetics. Br Med J (Clin Res Ed) (1983) 0.92
Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science (1998) 18.23
High sensitivity mapping of methylated cytosines. Nucleic Acids Res (1994) 16.62
Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ (1993) 7.14
Measuring the extent and effectiveness of protected areas as an indicator for meeting global biodiversity targets. Philos Trans R Soc Lond B Biol Sci (2005) 4.94
North of England evidence based guidelines development project: guideline for the primary care management of dementia. BMJ (1998) 4.39
Roles for Nkx3.1 in prostate development and cancer. Genes Dev (1999) 4.30
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
The natural history of Hendra and Nipah viruses. Microbes Infect (2001) 3.77
Not playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequate. BMJ (1999) 3.60
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci (2001) 3.50
North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. BMJ (1998) 3.14
Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol (1992) 3.14
A comparison of the reliability of self-reported drug use and sexual behaviors using computer-assisted versus face-to-face interviewing. AIDS Educ Prev (2000) 3.02
Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ (2000) 2.92
CpNpG methylation in mammalian cells. Nat Genet (1995) 2.88
Midwifery and body fluid contamination. BMJ (1992) 2.81
Structural basis for activation of the titin kinase domain during myofibrillogenesis. Nature (1998) 2.80
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis (1993) 2.78
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J (2004) 2.73
Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci U S A (1997) 2.54
Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene (1997) 2.50
A high-density integrated genetic linkage and radiation hybrid map of the laboratory rat. Genome Res (1999) 2.49
Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys (1992) 2.37
Brown adipose tissue in the parametrial fat pad of the mouse. FEBS Lett (1984) 2.36
Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ (2012) 2.33
Repeat heart valve surgery: risk factors for operative mortality. J Thorac Cardiovasc Surg (2001) 2.18
The endurance shuttle walking test: a responsive measure in pulmonary rehabilitation for COPD patients. Chron Respir Dis (2006) 2.09
An adherent dressing for aplasia cutis congenita. Br J Plast Surg (2005) 2.07
A request for the 'morning-after' pill. Practitioner (1989) 2.05
Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development (1999) 2.04
Carcinogenic activity of bracken. Nature (1965) 2.03
How to develop cost-conscious guidelines. Health Technol Assess (2001) 2.03
Severe carbon monoxide poisoning: outcome after hyperbaric oxygen therapy. Br J Anaesth (2000) 2.03
Preparation of interstitial lung cells by enzymatic digestion of tissue slices: preliminary characterization by morphology and performance in functional assays. Immunology (1985) 2.02
Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis (2005) 2.00
A validation study on the use of intra-operative video recording as an objective assessment tool for core ENT surgery. Clin Otolaryngol (2014) 1.98
Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med (2001) 1.97
Characterization of sheep afferent lymph dendritic cells and their role in antigen carriage. J Exp Med (1989) 1.97
Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res (1997) 1.95
A European consensus on outcome measures for psychosocial intervention research in dementia care. Aging Ment Health (2008) 1.94
Maternal and child health services in rural Nepal: does access or quality matter more? Health Policy Plan (2000) 1.93
Crystal structure of the alpha-actinin rod reveals an extensive torsional twist. Structure (2001) 1.85
Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure. Am J Med (1984) 1.83
Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol (1993) 1.82
Structure of the alpha-actinin rod: molecular basis for cross-linking of actin filaments. Cell (1999) 1.80
The effect of regular sunscreen use on vitamin D levels in an Australian population. Results of a randomized controlled trial. Arch Dermatol (1995) 1.79
Giant axonal neuropathy (GAN): case report and two novel mutations in the gigaxonin gene. Neurology (2002) 1.77
Cost-effectiveness league tables: more harm than good? Soc Sci Med (1993) 1.74
Economics of treatment of depression. Br J Psychiatry (1995) 1.74
forked proteins are components of fiber bundles present in developing bristles of Drosophila melanogaster. Genetics (1994) 1.73
Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombinants. J Mammary Gland Biol Neoplasia (1997) 1.73
Comorbidity of migraine and restless legs syndrome--a case-control study. Cephalalgia (2007) 1.71
Systematic review of topical treatments for fungal infections of the skin and nails of the feet. BMJ (1999) 1.70
Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol (2001) 1.69
Cardiovascular safety of fexofenadine HCl. Am J Cardiol (1999) 1.69
ICRP Publication 119: Compendium of dose coefficients based on ICRP Publication 60. Ann ICRP (2012) 1.69
The hydrophobic effect contributes to polyubiquitin chain recognition. Biochemistry (1998) 1.68
Association between early sexual abuse and adult HIV-risky sexual behaviors among community-recruited women. Child Abuse Negl (2001) 1.66
Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology (1998) 1.64
Continuing occurrence of thyroid carcinoma after irradiation to the neck in infancy and childhood. N Engl J Med (1975) 1.63
Reporting guidelines for economic studies. Health Econ (1995) 1.62
Prevention indicators for evaluating the progress of national AIDS programmes. AIDS (1994) 1.61
A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. J Bone Joint Surg Br (2002) 1.60
Self-reported symptoms of gynecological morbidity and their treatment in south India. Stud Fam Plann (1995) 1.60
Links between premarital sexual behaviour and extramarital intercourse: a multi-site analysis. AIDS (2000) 1.59
Combinatorial signaling codes for the progressive determination of cell fates in the Drosophila embryonic mesoderm. Genes Dev (1998) 1.59
Angioblast differentiation and morphogenesis of the vascular endothelium in the mouse embryo. Dev Biol (1991) 1.56
Clinical and economic consequences of dyspepsia in the community. Gut (2002) 1.55
Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. J Bone Joint Surg Am (1998) 1.51
Newspaper reporting of meticillin-resistant Staphylococcus aureus and 'the dirty hospital'. J Hosp Infect (2010) 1.51
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
Effect of meal viscosity and nutrients on satiety, intragastric dilution, and emptying assessed by MRI. Am J Physiol Gastrointest Liver Physiol (2001) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
Psychiatric illness and mortality after hip fracture. Lancet (2001) 1.49
Elevations of serum T3 levels and their association with symptoms in World War II veterans with combat-related posttraumatic stress disorder: replication of findings in Vietnam combat veterans. Psychosom Med (1999) 1.49
SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev (2000) 1.48
Migrant men: a priority for HIV control in Pakistan? Sex Transm Infect (2006) 1.48
Mechanical and constitutional risk factors for symptomatic knee osteoarthritis: differences between medial tibiofemoral and patellofemoral disease. J Rheumatol (1994) 1.48
Tracheo-innominate artery fistula after percutaneous tracheostomy: three case reports and a clinical review. Br J Anaesth (2005) 1.48
Can Wilson's disease patients be decoppered? Lancet (1989) 1.47
Increased prevalence of obstructive sleep apnoea in patients with Charcot-Marie-Tooth disease: a case control study. J Neurol Neurosurg Psychiatry (2008) 1.47
Early sexual debut among young men in rural South Africa: heightened vulnerability to sexual risk? Sex Transm Infect (2005) 1.47
A reconsideration of the Poisson hypothesis for transmitter release at the crayfish neuromuscular junction. J Physiol (1970) 1.43
A randomized trial of Evidence-based OutReach (EBOR): rationale and design. Control Clin Trials (1999) 1.42
Determination of the X(3872) meson quantum numbers. Phys Rev Lett (2013) 1.42
Fission yeast cdc25 is a cell-cycle regulated protein. Biochem Biophys Res Commun (1990) 1.41
Extracts from "Clinical evidence": Athlete's foot and fungally infected toenails. BMJ (2001) 1.41
Efficacy of camptothecin in progressive multifocal leucoencephalopathy. Lancet (1997) 1.40
Obtaining data from patients' records. Br Dent J (1995) 1.39
General practice estimates of the prevalence of common chronic conditions. Ir Med J (1992) 1.39
Plasma progesterone concentrations in llamas. Vet Rec (1990) 1.38